PFM
CRSP icon

Privium Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

Privium Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
44,974
+2,100
+5% +$111K 0.45% 34
2026
Q1 		$2.04M Hold
42,874
– – 0.42% 33
2025
Q4 		$2.25M Buy
42,874
+2,874
+7% +$172K 0.41% 31
2025
Q3 		$2.59M Sell
40,000
-4,700
-11% -$270K 0.47% 25
2025
Q2 		$2.17M Sell
44,700
-15,397
-26% -$596K 0.47% 22
2025
Q1 		$2.05M Buy
60,097
+25,100
+72% +$1.06M 0.53% 24
2024
Q4 		$1.38M Buy
34,997
+4,650
+15% +$220K 0.31% 30
2024
Q3 		$1.43M Buy
30,347
+3,000
+11% +$152K 0.35% 31
2024
Q2 		$1.45M Buy
27,347
+14,600
+115% +$845K 0.37% 39
2024
Q1 		$869K Hold
12,747
– – 0.23% 49
2023
Q4 		$842K Buy
12,747
+5,547
+77% +$307K 0.23% 46
2023
Q3 		$327K Buy
7,200
+1,200
+20% +$62K 0.1% 64
2023
Q2 		$342K Hold
6,000
– – 0.1% 65
2023
Q1 		$271K Buy
+6,000
New +$291K 0.09% 65
2022
Q2 		– Sell
-3,750
Closed -$235K – 269
2022
Q1 		$235K Buy
+3,750
New +$235K 0.05% 126

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Privium Fund Management's CRSP Position: Q2 2026 in Review

Privium Fund Management increased its CRISPR Therapeutics (CRSP) stake by 4.9% in Q2 2026, buying an estimated $111K and bringing the position to 44,974 shares worth $2.45M. The position accounts for 0.45% of the portfolio, ranked #34.

Privium Fund Management first reported a position in CRSP in Q1 2022 and has held it in 15 quarters since. The position peaked at $2.59M in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Privium Fund Management held 44,974 shares of CRISPR Therapeutics worth $2.45M as of Q2 2026.
  • Privium Fund Management bought 2,100 CRISPR Therapeutics shares in Q2 2026, an estimated $111K.
  • CRISPR Therapeutics made up 0.45% of Privium Fund Management's portfolio in Q2 2026, its #34 holding.
  • Privium Fund Management first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • Privium Fund Management's CRISPR Therapeutics position peaked at $2.59M in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.